Over the last decade iQur has worked in close conjunction with some of the world’s leading diagnostics companies to develop innovative tests for liver disease.
Initially working with Bayer Healthcare Diagnostics and now Siemens Healthcare Diagnostics, iQur developed the Enhanced Liver Fibrosis Test (ELF Test), a unique blood test that can asses the severity of liver damage in patients with a wide range of chronic liver diseases.
In collaboration with academia, industry and the NHS, iQur has taken discoveries made by investigators working in universities across Europe in studies led by Professor Rosenberg, to work with Siemens Healthcare Diagnostics to validate and gain regulatory approval for the ELF Test.
Subsequently iQur has provided a platform for investigators at UCL Institute for Liver and Digestive Health to collaborate with researchers across the world, conducting studies that have explored and validated the use of the ELF Test as one of the most accurate and reliable tests for liver fibrosis. This collaboration has spawned over 100 publications and presentations and has led to widespread use of the test for the benefit of patients and their doctors globally.
iQur continues to work in partnership with investigators seeking to use the ELF Test in their research, and with companies using the ELF Test as a surrogate marker of liver fibrosis in drug discovery.